---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-064475"
form_type: "8-K"
ticker: "LYRA"
cik: "0001327273"
company_name: "Lyra Therapeutics, Inc."
filed_at: "2025-05-06T23:59:59+00:00"
generated_at: "2026-05-22T11:11:17.496618+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.7
confidence: "high"
source: SEC EDGAR
---

# Lyra Therapeutics reports Q1 net loss of $8.5M; ENLIGHTEN 2 top-line results expected Q2 2025

## Summary
- Net loss of $8.5M ($0.13 per share) vs. $22.5M ($0.35) in Q1 2024; cash burn reduced YoY.
- Cash & equivalents $31.7M at March 31, 2025, down from $40.6M at Dec 31, 2024.
- Topline Phase 3 ENLIGHTEN 2 data for LYR-210 in CRS expected in Q2 2025; ~65 polyp patients across both ENLIGHTEN trials.
- Plans a reverse stock split to comply with Nasdaq $1.00 minimum bid; stockholder vote on May 14, 2025.
- R&D expenses fell to $4.9M from $18.2M YoY, driven by completion of BEACON and ENLIGHTEN 1 trials and May 2024 workforce reduction.

## SEC filing metadata
- accession: 0000950170-25-064475
- form_type: 8-K
- ticker: LYRA
- cik: 0001327273
- company_name: Lyra Therapeutics, Inc.
- filed_at: 2025-05-06T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.7
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1327273/000095017025064475/0000950170-25-064475-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1327273/000095017025064475/lyra-20250506.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-064475
- JSON: https://secwatch.observer/filing/0000950170-25-064475.json
- Plain text: https://secwatch.observer/filing/0000950170-25-064475.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.